Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02537444
Title ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191)
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

fallopian tube carcinoma

peritoneal carcinoma

ovary epithelial cancer

Therapies

Acalabrutinib

Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.